The BEACON CRC study compared encorafenib plus cetuximab with or without the MEK inhibitor binimetinib (Mektovi®; Array Biopharma) vs. IRI or FOLFIRI plus cetuximab in previously treated patients with the BRAF V600E mutation. The gene discussed is BRAF; the disease is colorectal carcinoma.